{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:35:20Z","timestamp":1792154120731,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.antiviral.2012.12.006","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T01:10:10Z","timestamp":1355965810000},"page":"154-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus"],"prefix":"10.1016","volume":"97","author":[{"given":"Koji","family":"Chono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyomitsu","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiyasu","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2012.12.006_b0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1128\/AAC.18.3.443","article-title":"In vitro susceptibility of varicella-zoster virus to acyclovir","volume":"18","author":"Biron","year":"1980","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.12.006_b0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.antiviral.2003.09.006","article-title":"Treatment of herpes simplex virus infections","volume":"61","author":"Brady","year":"2004","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.12.006_b0015","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","article-title":"ASP2151, a novel helicase\u2013primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2","volume":"65","author":"Chono","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2012.12.006_b0020","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nm0402-386","article-title":"Herpes simplex virus helicase\u2013primase inhibitors are active in animal models of human disease","volume":"8","author":"Crute","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2012.12.006_b0025","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2012.12.006_b0030","doi-asserted-by":"crossref","first-page":"32154","DOI":"10.1074\/jbc.273.48.32154","article-title":"The herpes simplex virus type 1 helicase\u2013primase. Analysis of helicase activity","volume":"273","author":"Falkenberg","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2012.12.006_b0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaad.2007.06.027","article-title":"Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management","volume":"57","author":"Fatahzadeh","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.antiviral.2012.12.006_b0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.drup.2010.11.002","article-title":"Antiviral drug resistance and helicase\u2013primase inhibitors of herpes simplex virus","volume":"14","author":"Field","year":"2011","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.antiviral.2012.12.006_b0045","first-page":"331","article-title":"Comparison of the effects of arabinosyladenine, arabinosylhypoxanthine, and arabinosyladenine 5\u2032-monophosphate against herpes simplex virus, varicella-zoster virus, and cytomegalovirus with their effects on cellular deoxyribonucleic acid synthesis","volume":"47","author":"Gephart","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.12.006_b0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"Greco","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.antiviral.2012.12.006_b0055","first-page":"5318","article-title":"Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine","volume":"50","author":"Greco","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2012.12.006_b0065","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1099\/0022-1317-82-11-2761","article-title":"Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir","volume":"82","author":"Kamiyama","year":"2001","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2012.12.006_b0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/095632020401500303","article-title":"Helicase primase: targeting the Achilles heel of herpes simplex viruses","volume":"15","author":"Kleymann","year":"2004","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2012.12.006_b0075","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase\u2013primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2012.12.006_b0080","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1124\/jpet.109.160630","article-title":"Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir","volume":"333","author":"Kuramoto","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.antiviral.2012.12.006_b0085","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-3565(24)29548-3","article-title":"Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo","volume":"297","author":"Kurokawa","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.antiviral.2012.12.006_b0090","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1128\/JVI.70.3.1759-1767.1996","article-title":"Functional order of assembly of herpes simplex virus DNA replication proteins into prereplicative site structures","volume":"70","author":"Liptak","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.12.006_b0095","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1128\/AAC.47.1.106-117.2003","article-title":"In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates","volume":"47","author":"Meletiadis","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.12.006_b0100","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.1016\/S0021-9258(20)79686-9","article-title":"Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase","volume":"255","author":"Miller","year":"1980","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2012.12.006_b0105","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1016\/0006-2952(82)90305-7","article-title":"Phosphorylation of acyclovir diphosphate by cellular enzymes","volume":"31","author":"Miller","year":"1982","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2012.12.006_b0110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.antiviral.2004.10.002","article-title":"Comparative efficacy of acyclovir and vidarabine on the replication of varicella-zoster virus","volume":"65","author":"Miwa","year":"2005","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.12.006_b0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1386-6532(02)00263-9","article-title":"Herpes simplex virus resistance to antiviral drugs","volume":"26","author":"Morfin","year":"2003","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2012.12.006_b0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1749-6632.1977.tb21935.x","article-title":"Inhibition of herpesvirus DNA synthesis by 9-beta-D-arabinofuranosyladenine in cellular and cell-free systems","volume":"284","author":"Muller","year":"1977","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.antiviral.2012.12.006_b0125","doi-asserted-by":"crossref","first-page":"15619","DOI":"10.1074\/jbc.R111.233981","article-title":"Replication and recombination of herpes simplex virus DNA","volume":"286","author":"Muylaert","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2012.12.006_b0130","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1099\/0022-1317-44-3-715","article-title":"Mechanism of acquired resistance to herpes simplex virus infection as studied in nude mice","volume":"44","author":"Nagafuchi","year":"1979","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2012.12.006_b0135","series-title":"Fields Virology","first-page":"2479","article-title":"The family Herpesviridae: a brief introduction","author":"Pellet","year":"2007"},{"key":"10.1016\/j.antiviral.2012.12.006_b0140","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1128\/AAC.38.6.1246","article-title":"Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients","volume":"38","author":"Safrin","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.12.006_b0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0002-9343(82)90061-4","article-title":"Different in vitro effects of dual combinations of anti-herpes simplex virus compounds","volume":"73","author":"Schinazi","year":"1982","journal-title":"Am. J. Med."},{"key":"10.1016\/j.antiviral.2012.12.006_b0150","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/0006-2952(84)90715-9","article-title":"Metabolism of arabinosyladenine in herpes simplex virus-infected and uninfected cells. Correlation with inhibition of DNA synthesis and role in antiviral selectivity","volume":"33","author":"Schwartz","year":"1984","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2012.12.006_b0155","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/jmv.20990","article-title":"Genital herpes due to acyclovir-sensitive herpes simplex virus caused secondary and recurrent herpetic whitlows due to thymidine kinase-deficient\/temperature-sensitive virus","volume":"79","author":"Shimada","year":"2007","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2012.12.006_b0160","first-page":"17","article-title":"Isolation of drug resistant mutants of varicella-zoster virus: cross resistance of acyclovir resistant mutants with phosphonoacetic acid and bromodeoxyuridine","volume":"26","author":"Shiraki","year":"1983","journal-title":"Biken J."},{"key":"10.1016\/j.antiviral.2012.12.006_b0165","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.antiviral.2006.05.001","article-title":"Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus","volume":"72","author":"Suzuki","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.12.006_b0170","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0022-3565(24)29450-7","article-title":"Drug synergism: its detection and applications","volume":"298","author":"Tallarida","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl 2","key":"10.1016\/j.antiviral.2012.12.006_b0175","first-page":"57A","article-title":"Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret\u2019s","volume":"11","author":"Tyler","year":"2004","journal-title":"Herpes"},{"key":"10.1016\/j.antiviral.2012.12.006_b0180","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/jis019","article-title":"ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study","volume":"205","author":"Tyring","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.12.006_b0185","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/clinids\/20.2.414","article-title":"Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations","volume":"20","author":"Whitley","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.12.006_b0190","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","article-title":"Herpes simplex virus infections","volume":"357","author":"Whitley","year":"2001","journal-title":"Lancet"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212002860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212002860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T01:01:18Z","timestamp":1745456478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354212002860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0166354212002860"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2012.12.006","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2012.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}